Exchange Unable to Decide on Kolon TissueGene Delisting... To Reconsider Review
[Asia Economy Reporter Choi Dae-yeol] The Korea Exchange KOSDAQ Market Division held a KOSDAQ Market Committee meeting regarding the Kolon TissueGene stock, which has grounds for delisting, but announced on the 7th that the review was not completed and will be resumed later.
Hot Picks Today
Cerebras Soars 70% on IPO Debut: Is Nvidia's Reign Ending as a New AI Semiconductor Power Emerges?
- After Surpassing 8,000 Points, Is Profit-Taking Underway?... Why Is the KOSPI Plunging?
- "Multi-Million Won Bonuses, Life Is Sweet"—Even Employee Reactions... SK hynix Overtakes Samsung to Claim No. 1 Spot
- "Gave in to the Momentary Temptation": Japanese Police Official Dismissed After Stealing 100 Million Won Next to Body
- "After Vowing to Become No. 1 Globally, Sudden Policy Brake Puts Companies’ Massive Investments at Risk"
This content was produced with the assistance of AI translation services.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
